Kiora Pharmaceuticals Inc... (KPRX)
2.77
-0.16 (-5.46%)
At close: Apr 02, 2025, 3:58 PM
2.87
3.61%
After-hours: Apr 02, 2025, 07:44 PM EDT
-5.46% (1D)
| Bid | 2.63 |
| Market Cap | 8.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | 0.87 |
| PE Ratio (ttm) | 3.18 |
| Forward PE | -1.54 |
| Analyst | Buy |
| Ask | 2.96 |
| Volume | 17,255 |
| Avg. Volume (20D) | 31,533 |
| Open | 2.81 |
| Previous Close | 2.93 |
| Day's Range | 2.72 - 2.92 |
| 52-Week Range | 2.72 - 5.76 |
| Beta | -0.46 |
About KPRX
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, a...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 13, 2015
Employees 12
Stock Exchange NASDAQ
Ticker Symbol KPRX
Website https://www.kiorapharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for KPRX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 261.01% from the latest price.
Stock ForecastsEarnings Surprise
Kiora Pharmaceuticals has released their quartely earnings
on Mar 25, 2025:
Next Earnings Release
Kiora Pharmaceuticals Inc. is scheduled to release its earnings on May 9, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
